---
title: "CITIC International: Raises WuXi AppTec target price to HKD 131, maintains \"Outperform\" rating"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/263936033.md"
description: "Jianyin International released a research report stating that it has raised the target price for WuXi AppTec by 7.4%, from HKD 122 to HKD 131, maintaining an \"outperform\" rating. The firm indicated that despite the imminent implementation of the \"U.S. Biosecurity Act 2.0,\" the company continues to expand its range of drugs while still providing customer services for GLP-1 targeted drugs. The firm noted that the company's Q3 2025 performance exceeded expectations, with net profit increasing from RMB 2.3 billion in the same period of 2024 to RMB 3.5 billion, and total revenue growing by 15% year-on-year to RMB 12.1 billion. Chemical Conjugates (TIDES) will contribute to the company's growth, with TIDES revenue in the first three quarters of 2025 increasing by 121% year-on-year to RMB 7.8 billion, primarily due to a 17% year-on-year increase in TIDES backlog orders. Given the continued growth in demand for TIDES from overseas clients, the firm has raised its total revenue forecasts for 2026 and 2027 by 2% and 3%, respectively, to RMB 51.9 billion and RMB 58.5 billion; due to improved gross margins and a decrease in the ratio of operating expenses to sales, the core profit expectations for 2026 and 2027 have been raised by 9% and 12% to RMB 15.3 billion and RMB 17.7 billion, respectively"
datetime: "2025-11-03T03:37:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263936033.md)
  - [en](https://longbridge.com/en/news/263936033.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263936033.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/263936033.md) | [繁體中文](https://longbridge.com/zh-HK/news/263936033.md)


# CITIC International: Raises WuXi AppTec target price to HKD 131, maintains "Outperform" rating

According to the Zhitong Finance APP, Jianyin International has released a research report stating that it has raised the target price for WuXi AppTec (02359) by 7.4%, from HKD 122 to HKD 131, maintaining an "outperform" rating. The firm indicated that despite the imminent implementation of the "U.S. Biosecurity Act 2.0," the company continues to expand its drug range while still providing customer services for GLP-1 targeted drugs. The firm noted that the company's Q3 2025 performance exceeded expectations, with net profit increasing from RMB 2.3 billion in the same period of 2024 to RMB 3.5 billion, and total revenue growing by 15% year-on-year to RMB 12.1 billion.

Chemical conjugates (TIDES) will contribute to the company's growth, with TIDES revenue increasing by 121% year-on-year to RMB 7.8 billion in the first three quarters of 2025, primarily due to a 17% annual increase in TIDES backlog orders. Given the continued growth in demand for TIDES from overseas clients, the firm has raised its total revenue forecasts for 2026 and 2027 by 2% and 3% respectively, reaching RMB 51.9 billion and RMB 58.5 billion; due to improved gross margins and a decrease in the ratio of operating expenses to sales, the core profit expectations for 2026 and 2027 have been raised by 9% and 12% respectively to RMB 15.3 billion and RMB 17.7 billion

### 相关股票

- [WuXi AppTec (603259.CN)](https://longbridge.com/zh-CN/quote/603259.CN.md)
- [WUXI APPTEC (02359.HK)](https://longbridge.com/zh-CN/quote/02359.HK.md)

## 相关资讯与研究

- [WuXi AppTec Jumps After Chinese Drugmaker Raises 2025 Earnings Forecast Again](https://longbridge.com/zh-CN/news/272383291.md)
- [Astellas Speeds Pipeline, Eyes 10 Late-Stage Drugs by 2034](https://longbridge.com/zh-CN/news/281117306.md)
- [14:37 ETLevrx and Waltz Health Partner to Expand Access to Transparent Pharmacy Pricing](https://longbridge.com/zh-CN/news/281411704.md)
- [BullFrog AI Signs Major AI Drug Discovery Partnership](https://longbridge.com/zh-CN/news/281092205.md)
- [TippingPoint Biosciences Raises $4.5M Seed to Drug Hidden Epigenetic Targets in Deadly Pediatric Brain Cancer](https://longbridge.com/zh-CN/news/281175947.md)